Abiomed launches quality assurance program for Impella heart pump

Abiomed (NSDQ:ABMD) said today it launched the Impella quality assurance program, looking to improve outcomes for cardiogenic shock and protected PCI patients. The Danvers, Mass.-based company said the program will use data from its IQ Database, which includes observational quality assurance data on over 95% of Impella patients since 2008, including more than 44,000 Impella case entries. The IQ program will complement best practices alongside Abiomed’s 250-person clinical field team, the company said. “Abiomed has created the largest high-risk PCI and cardiogenic shock database of real-world evidence with different levels of analysis from observational quality assessment, to IRB prospective registries, to FDA prospective randomized studies. We believe that by sharing our data-driven insights and clinical expertise, we can help hospitals create protocols, processes, and best practices to improve outcomes in Protected PCI and cardiogenic shock around native heart recovery,” prez, chair & CEO Michael Minogue said in a press release. The program is part of Abiomed’s education and training initiatives, the company said, which has a goal of “positively affecting both survival and recovery outcomes for this very high-risk patient population.” The company said it invested more than $85 million in its collection of real-world data. Last week, Abiomed saw shares dip after it missed the Street’s expectations for its 2nd quarter, despite toutin...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Cardiovascular Abiomed Inc. Source Type: news